197 related articles for article (PubMed ID: 18618292)
1. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.
Bonnetain F; Paoletti X; Collette S; Doffoel M; Bouché O; Raoul JL; Rougier P; Masskouri F; Barbare JC; Bedenne L
Qual Life Res; 2008 Aug; 17(6):831-43. PubMed ID: 18618292
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.
Collette S; Bonnetain F; Paoletti X; Doffoel M; Bouché O; Raoul JL; Rougier P; Masskouri F; Bedenne L; Barbare JC
Ann Oncol; 2008 Jun; 19(6):1117-26. PubMed ID: 18303031
[TBL] [Abstract][Full Text] [Related]
3. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.
Diouf M; Filleron T; Barbare JC; Fin L; Picard C; Bouché O; Dahan L; Paoletti X; Bonnetain F
J Hepatol; 2013 Mar; 58(3):509-21. PubMed ID: 23178978
[TBL] [Abstract][Full Text] [Related]
4. The association of liver function and quality of life of patients with liver cancer.
Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W
BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
[TBL] [Abstract][Full Text] [Related]
7. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.
Diouf M; Bonnetain F; Barbare JC; Bouché O; Dahan L; Paoletti X; Filleron T
Oncologist; 2015 Jan; 20(1):62-71. PubMed ID: 25542450
[TBL] [Abstract][Full Text] [Related]
8. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.
Tateishi R; Yoshida H; Shiina S; Imamura H; Hasegawa K; Teratani T; Obi S; Sato S; Koike Y; Fujishima T; Makuuchi M; Omata M
Gut; 2005 Mar; 54(3):419-25. PubMed ID: 15710994
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.
Tournoux-Facon C; Paoletti X; Barbare JC; Bouché O; Rougier P; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Bedenne L; Bonnetain F
J Hepatol; 2011 Jan; 54(1):108-14. PubMed ID: 21047696
[TBL] [Abstract][Full Text] [Related]
10. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study.
Borzio M; Dionigi E; Rossini A; Marignani M; Sacco R; De Sio I; Bertolini E; Francica G; Giacomin A; Parisi G; Vicari S; Toldi A; Salmi A; Boccia S; Mitra M; Fornari F
Hepatology; 2018 Jun; 67(6):2215-2225. PubMed ID: 29165831
[TBL] [Abstract][Full Text] [Related]
11. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
[TBL] [Abstract][Full Text] [Related]
12. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma.
Yeo W; Mo FK; Koh J; Chan AT; Leung T; Hui P; Chan L; Tang A; Lee JJ; Mok TS; Lai PB; Johnson PJ; Zee B
Ann Oncol; 2006 Jul; 17(7):1083-9. PubMed ID: 16600982
[TBL] [Abstract][Full Text] [Related]
13. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
[TBL] [Abstract][Full Text] [Related]
14. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.
Hepatology; 1998 Sep; 28(3):751-5. PubMed ID: 9731568
[TBL] [Abstract][Full Text] [Related]
15. Role functioning is associated with survival in patients with hepatocellular carcinoma.
Meier A; Yopp A; Mok H; Kandunoori P; Tiro J; Singal AG
Qual Life Res; 2015 Jul; 24(7):1669-75. PubMed ID: 25502092
[TBL] [Abstract][Full Text] [Related]
16. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
17. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
19. An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma.
Rabe C; Lenz M; Schmitz V; Pilz T; Fimmers R; Sauerbruch T; Caselmann WH
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1305-15. PubMed ID: 14624154
[TBL] [Abstract][Full Text] [Related]
20. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.
Yau T; Yao TJ; Chan P; Ng K; Fan ST; Poon RT
Cancer; 2008 Nov; 113(10):2742-51. PubMed ID: 18853421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
